-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $6

Benzinga·05/08/2026 11:19:24
Listen to the news
HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) with a Buy and lowers the price target from $25 to $6.